ArticleAnnals of hematology2026
Cyclosporine related adverse events in aplastic anemia patients treated with immunosuppressive therapy.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundFew studies have focused on cyclosporine-related adverse events (AEs) in aplastic anemia (AA) patients undergoing immunosuppressive therapy and receive cyclosporine maintenance. MATERIALS AND
methodsWe conducted a retrospective study to analyze the relationship between cyclosporine concentrations at different time points and AEs in AA patients who received cyclosporine maintenance. Cutoff values of cyclosporine concentrations for predicting every AE were defined by receiver operating characteristic (ROC) curves respectively.
resultsA total of 382 patients were included. The most common AEs included hypertrichosis (72.3%), gingival hyperplasia (60.5%), hyperuricemia (62.6%), hyperlipidemia (47.0%), and elevated creatinine levels (39.9%). Patients presented with AEs were with higher C0 (trough) and C2 (peak) levels. Most of the values of C0 and C2 were in the ranges of 200-250 μg/L and 700-1000 μg/L, respectively. Patients with C0 higher than 250 μg/L or C2 higher than 1000 μg/L were more likely to develop AEs. Response rate was not associated with cyclosporine concentrations, but C0 levels below 150 μg/L or C2 levels below 500 μg/L showed lower response trend. Based on these findings, we propose a therapeutic range of 150-250 μg/L for C0 and 500-1000 μg/L for C2. This range is intended to balance maintaining therapeutic efficacy with minimizing the risk of adverse events. Then we propose a dose of 4.5-5.5 mg/kg/d for patients under 40 years old and 3.5-4.5 mg/kg/d for those over 40 years old to achieve target concentrations.
conclusionIn summary, we provide a comprehensive analysis of AEs associated with cyclosporine maintenance in AA patients undergoing IST. We also propose optimal cyclosporine concentration ranges and suggest age-adjusted dosing strategies to ensure both efficacy and safety. KEY MESSAGES: (1) AA Patients presented with cyclosporine associated AEs were with higher C0 (trough) and C2 (peak) levels. (2) We recommend the optimal concentration ranges as 150-250 μg/L for C0 and 500-1000 μg/L for C2 for AA patients receive cyclosporine treatment. (3) We propose a dose of 4.5-5.5 mg/kg/d for patients under 40 years old and 3.5-4.5 mg/kg/d for those over 40 years old to achieve target concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.